Table 2. Comparison of clinicopathologic characteristics of group A with group B.
| Characteristic | Total | Group A | Group B | p-value | ||
|---|---|---|---|---|---|---|
| Univariate | Multivariate | OR (95% CI) | ||||
| Total number of patients | 124 (100.0) | 88 (71.0) | 36 (29.0) | |||
| Age (y) | 64.19±7.83 | 63.13±8.19 | 66.75±6.27 | 0.010 | 0.004 | 1.107 (1.032–1.187) |
| Interval (mo) | 21.44±16.14 | 21.18±16.24 | 22.08±16.12 | 0.779 | ||
| PSA of initial biopsy (ng/mL) | 6.78±3.30 | 6.82±3.14 | 6.69±3.71 | 0.843 | ||
| PSA of repeat biopsy (ng/mL) | 8.83±8.91 | 8.85±10.13 | 8.78±4.87 | 0.968 | ||
| Prostate volume (cm3)a | 50.29±19.59 | 52.26±18.16 | 45.48±22.28 | 0.081 | ||
| PSA velocity (ng • mL-1 • year-1) | 1.52±10.29 | 1.38±11.90 | 1.85±4.51 | 0.820 | ||
| PSA density (ng/mL2) | 0.14±0.08 | 0.13±0.08 | 0.16±0.09 | 0.062 | ||
| Pathology of initial biopsy | 0.066 | |||||
| Benign | 66 (53.2) | 48 (54.5) | 18 (50.0) | |||
| 1≤HGPIN≤2 | 32 (25.8) | 26 (29.5) | 6 (16.7) | |||
| ASAP or HGPIN ≥3 | 26 (21.0) | 14 (15.9) | 12 (33.3) | |||
| De Ritis ratiob | 1.42±0.50 | 1.34±0.56 | 1.61±0.24 | 0.001 | 0.024 | 2.670 (1.135–6.280) |
Values are presented as number (%) or mean±standard deviation.
Group A, benign or low-risk prostate cancer; group B, non-low-risk prostate cancer; OR, odds ratio; CI, confidence interval; PSA, prostate-specific antigen; HGPIN, high-grade prostatic intraepithelial neoplasia; ASAP, atypical small acinar proliferation.
a:Prostate volume was measured by transrectal ultrasonography. b:De Ritis ratio: aspartate aminotransferase/alanine aminotransferase.